Fudan and Xiamen University have teamed up for the first time to develop a new strategy to stop the growth of NRAS mutant melanoma
-
Last Update: 2021-02-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
is one of the deadliest types of skin cancer and is notorious for its resistance to conventional chemotherapy. About 25 percent of melanomas are driven by cancer-causing mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, there are currently no effective drugs targeting NRAS.
In a new study, researchers from Fudan University in China, Xiamen University and Boston University School of Medicine in the United States have discovered a new NRAS active agent and developed a specific inhibitor that effectively blocks the growth of NRAS mutant melanoma (NRAS mutant melanoma). These findings offer a promising treatment option for the treatment of NRAS mutant melanoma. The findings, published online January 31, 2019 in the journal Cell, are titled "Pharmacological Targeting of STK19 Oncogenic NRAS-Driven Melanomagenesis."
the researchers first discovered that STK19, an enzyme encoded by the STK19 gene, is a key regulatory factor for NRAS function. They then described the mechanism by which STK19 phosphates NRAS to activate NRAS through bio-chemical and cellular experiments. Finally, they designed a STK19 inhibitor called ZT-12-037-01, which effectively blocks NRAS activation and the production of NRAS mutant melanoma in experimental animal models.
study provides a promising treatment strategy for melanoma. In addition, this STK19 inhibitor may provide a treatment option for 25% of cancers with RAS mutations. The researchers hope their findings will eventually translate into better treatments for cancer patients. (Bio Valley)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.